| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Immunology | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Immunology | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Immunology |
Recent Updates
Recently added Catalysts
KalVista Pharmaceuticals, Inc.
$27
0 (0%)
Last traded Jun 10, 2026. This price is not current.
C 42Pipeline Score Richly Valued Pharma · Commercial
Market Cap
1.43 B
EPS
-
P/E Ratio
-
Value Trade
173.31 M
0.04 %
Week
34.96 %
1 Month
71.62 %
3 Month
106.55 %
6 Month
4 %
5 Year
-70.57 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
4.27 M
52 Week Range
9.83 - 26.85
% held by Insiders
17.04 %
% held by Institutions
115.54 %
Enterprise Value
1.43 B
Total Shares
50.58 M
Short %
19.69 %
Float Shares
34.75 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-06-17 | Sebetralstat | PDUFA Date | PDUFA | Approved | – | – | – |
2025-06-17 | Sebetralstat | PDUFA Date | PDUFA | Approved | – | – | – |
2025-06-17 | Sebetralstat | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
C42
Pipeline Score $210M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 66%
Micro Cap (rank 318 of 933)
Percentile RankKalVista Pharmaceuticals, Inc. carries a moderate pipeline score (42/100), with $524M risk-adjusted pipeline value, led by KVD900 in Hereditary Angioedema (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KVD900 Small molecule | Hereditary Angioedema | Phase 3 | NCT04349800 | 58% | $363M | COMPLETED | 496 | - | - | Sep 10, 2018 | ELEVATED_RISK | Apr 29, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sebetralstat | hereditary angioedema | Phase 3 | 2026-03-02 | attacks treated: 2464; second dose use: 19.3%; conventional treatment use: 5.1%; patient satisfaction: 83.1%; total attacks reported: 2077; oral sebetralstat use: 82.1%; untreated attacks: 1.9%; conventional use decrease: 21% to 13%; sebetralstat use increase: 76% to 85% Read More | KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) Read More | |
sebetralstat | hereditary angioedema | Phase 3 | 2026-03-02 | attacks treated: 2464; second dose use: 19.3%; conventional treatment use: 5.1%; patient satisfaction: 83.1%; total attacks reported: 2077; oral sebetralstat use: 82.1%; untreated attacks: 1.9%; conventional use decrease: 21% to 13%; sebetralstat use increase: 76% to 85% Read More | KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) Read More | |
sebetralstat | hereditary angioedema | Phase 3 | 2026-03-02 | attacks treated: 2464; second dose use: 19.3%; conventional treatment use: 5.1%; patient satisfaction: 83.1%; total attacks reported: 2077; oral sebetralstat use: 82.1%; untreated attacks: 1.9%; conventional use decrease: 21% to 13%; sebetralstat use increase: 76% to 85% Read More | KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KALV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KALV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How KALV ranks across every disease it competes inCompetitive Position is a premium feature
See how KALV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial